Treatment
Single Agent Therapy clinical trials
We’re tracking 99 recruiting studies that include Single Agent Therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT07148960Enrolling by invitationPhase 4
Does early dual therapy improve outcomes for staph bloodstream infections?
This study looks at whether giving two antibiotics early for a serious staph infection in the blood leads to better results than the standard one antibiotic. It uses existing hospital monitoring and follow-up visits to track progress.
Morgantown, West VirginiaAges 18 years+ - NCT06535568Recruiting
Comparing one vs two blood thinners after heart artery balloon treatment
This trial tests whether taking just one blood thinner (clopidogrel) is as safe and effective as taking two (clopidogrel plus aspirin) for older adults or people at high bleeding risk who have had a drug-coated balloon procedure to open blocked heart arteries.
Milan, MIAges Any age - NCT07025226RecruitingEarly Phase 1
Combination drugs and vaccine for glioma with remaining tumor
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Rochester, MinnesotaAges 18 years+ - NCT03445949RecruitingPhase 4
Best blood-thinner plan after a left heart device procedure
This trial compares which two medicines work best after a device closes off a part of the heart called the left atrial appendage. It may help reduce stroke risk while balancing bleeding risk after your procedure.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT05660811RecruitingPhase 4
Antiplatelet medicines after left atrial closure in dialysis patients
This trial looks at the best blood-thinning (antiplatelet) plan after a left atrial appendage closure procedure in people with kidney failure on dialysis. It may help reduce stroke risk while also lowering medicine-related side effects.
Warsaw, Masovian VoivodeshipAges 18 years+ - NCT06016062RecruitingPhase 1/Phase 2
Study of RC148 for advanced solid tumors
This trial tests a new drug called RC148, both alone and combined with other treatments, for people with advanced solid tumors that haven't responded to standard therapy. It includes several groups for specific cancers (like non-small cell lung, cervical, stomach, and ovarian cancer) to see if RC148 can shrink tumors or slow their growth.
AnhuiAges 18 years+ - NCT04494503RecruitingPhase 1/Phase 2
Study drug for hard-to-treat CLL or SLL after relapse
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06528691RecruitingPhase 2
Entrectinib for young children with NTRK/ROS1 brain tumors
This trial tests a targeted drug (entrectinib) in very young children (under 3) with a newly diagnosed brain tumor that has a specific genetic change (NTRK or ROS1 fusion). The drug works by blocking signals that help the tumor grow, and is given as the first treatment, before any chemotherapy or radiation.
Memphis, TennesseeAges Up to 3 years - NCT06549946RecruitingPhase 1/Phase 2
Ixovex-1 injection alone or with another drug for advanced solid tumors
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
LondonAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT04501120RecruitingPhase 1/Phase 2
Study drug for relapsed AML and related blood cancers
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05266612RecruitingPhase 1
Testing a cancer medicine for advanced solid tumors with HSV
This early (Phase 1) study tests VG2025, given alone or with nivolumab, in people with advanced solid cancers that have not responded to standard treatment. It may help by activating an immune response against cancer, especially in people who have HSV (herpes simplex virus) in their system.
Gilbert, ArizonaAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Gilbert, ArizonaAges 18–75 - NCT06599619Recruiting
Study of PD1 therapy on atypical moles in melanoma patients
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05577988RecruitingPhase 3
Genetic-guided weaker blood thinner vs stronger standard therapy
This study tests whether switching early to a weaker anti-platelet medicine based on your genetics can reduce bleeding problems in people at high risk for bleeding after a heart attack. It compares this approach to the usual strategy of staying on a stronger anti-platelet medicine.
Paris, IDFAges 18 years+ - NCT06007222RecruitingPhase 4
No blood thinners after TAVI: a trial for heart valve patients
This trial is for people who have had a TAVI procedure to replace a narrowed heart valve, and it tests whether it is safe to skip blood thinners afterward. The goal is to find the best way to protect your health without unnecessary medication.
Shinjuku, TokyoAges 20 years+ - NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT06119685RecruitingPhase 1/Phase 2
IDP-023 alone or with other antibodies for blood cancers
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT06589596RecruitingPhase 1
Study of BGB-58067 for advanced solid tumors
This trial tests an experimental drug called BGB-58067, either alone or with other cancer treatments, for people with advanced solid tumors that have stopped responding to standard therapy. It may be an option if you have a specific genetic change (loss of MTAP) in your tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05789082RecruitingPhase 1/Phase 2
Divarasib for untreated lung cancer with KRAS G12C
This trial studies divarasib to see if it is safe and can shrink or control advanced lung cancer. Participants must have a KRAS G12C mutation and have not had prior treatment for their advanced disease.
Duarte, CaliforniaAges 18 years+ - NCT04215809RecruitingPhase 1
Study drug for CLL or SLL after prior treatment failure
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
Duarte, CaliforniaAges 18–85 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+
What Single Agent Therapy is being studied for
Conditions with recruiting Single Agent Therapy studies.
Common questions
- Are there clinical trials studying Single Agent Therapy?
- Yes. Clin2 currently lists 99 recruiting studies that include Single Agent Therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Single Agent Therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Single Agent Therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Single Agent Therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.